Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women



Status:Active, not recruiting
Conditions:Contraception, Contraception
Therapuetic Areas:Reproductive
Healthy:No
Age Range:21 - 44
Updated:3/31/2019
Start Date:September 30, 2013
End Date:January 20, 2025

Use our guide to learn which trials are right for you!

A Multi-Center, Multi-National Clinical Study to Evaluate the Safety and Effectiveness of the Essure® (Model ESS505) Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception

The Essure System is indicated for women who desire non-incisional permanent birth control
(female sterilization) by occlusion of the fallopian tubes. The objective of the study is to
evaluate the safety and effectiveness of the Essure System (Model ESS505) for permanent birth
control in preventing pregnancy. The Essure ESS505 System includes a design modification that
will be studied to determine if it provides immediate birth control, thereby removing the
three months waiting period required for the commercially available Essure System Model 305
to be effective.


Inclusion Criteria:

- Female, 21 to 44 years of age, inclusive

- Body weight within range of 90-300 lbs (40 - 136 kg)

- Sexually active (minimum of 4 coital acts per cycle)

- Willing to accept the risk of pregnancy while relying solely on the inserts for
contraception

- Medical history indicates bilateral viable and patent fallopian tubes

- Agrees to fulfill local requirements for counseling and consent to contraception and
sterilization, including any required waiting periods

Exclusion Criteria:

- Post-menopausal woman

- Suspected or confirmed pregnancy

- Post-partum or pregnancy termination ≤6 weeks of scheduled insert placement

- Past fallopian tube sterilization procedure and/or total or partial salpingectomies

- Diagnosis of any of the following: tubal, endometrial, or myometrial pathology (which
may prevent fallopian tube ostia access), proximal tubal occlusion in either fallopian
tube, unicornuate uterus, active or recent upper or lower pelvic infection,
gynecologic malignancy

- Currently taking corticosteroids

- Known allergy to all contrast media available for use in hysterosalpingogram

- Scheduled to undergo concomitant intrauterine procedures at the time of insert
placement (intrauterine device removal is not considered a concomitant procedure)

- Any general health condition or systemic disease that may represent, in the opinion of
the physician, a potential increased risk associated with device use or pregnancy
We found this trial at
17
sites
?
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Arlington Heights, Illinois 60004
?
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
?
mi
from
Asheville, NC
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Bronx, NY
Click here to add this to my saved trials
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
?
mi
from
Hamilton,
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Irving, TX
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Newburgh, IN
Click here to add this to my saved trials
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Saginaw, MI
Click here to add this to my saved trials
?
mi
from
Spokane, WA
Click here to add this to my saved trials